Davis Polk advised the joint book-running managers in connection with a $260.8 million SEC-registered offering of 3,622,500 shares of common stock of Loxo Oncology, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “LOXO.”
Based in Stamford, Connecticut, Loxo Oncology, Inc. is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Loxo Oncology’s pipeline focuses on cancers that are uniquely dependent on single-gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Tyler P. Pender and Ingrid L. Perez. The tax team included partner Rachel D. Kleinberg and associate Catherine L. Chu. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.